Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02870907 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

Study acronym: RB SFCE 09
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 27 of 27 sites
    v13
  2. Re-verified, no change to tracked fieldsv12
  3. Primary completion date: Mar 2030 to Mar 1, 2031
    • Enrollment target: 185 to 195
    • Study completion date: Sep 2030 to Mar 1, 2031
    • Start date: Mar 2010 to Mar 18, 2010
    v11
  4. Site contacts updated at 1 of 27 sitesv10
  5. Re-verified, no change to tracked fieldsv9
Show 7 earlier versionsHide 7 earlier versions
  1. Primary completion date: Mar 2029 to Mar 2030
    • Study completion date: Sep 2029 to Sep 2030
    • Site contacts updated at 4 of 27 sites
    v8
  2. 2 versions Re-verified since Feb 11, 2020, no change to tracked fieldsv6-v7
  3. Enrollment target: 125 to 185
    • Site details revised at 1 of 27 sites
    v5
  4. Primary completion date: Mar 2026 to Mar 2029
    • Study completion date: Sep 2026 to Sep 2029
    • Site contacts updated at 2 of 27 sites
    v4
  5. Site details revised at 4 of 27 sitesv3
  6. Site contacts updated at 2 of 27 sitesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Curie
43 trials monitored
See 1 trial at risk
Postoperative Treatment of Unilateral Retinoblastoma After Primary Enucleation according to histopathological risk factors of the International Retinoblastoma Staging Working Group.
Trial Details
NCT Number NCT02870907
Lead Sponsor Institut Curie
Conditions
(from sponsor)		 Retinoblastoma
Related terms Retinoblastoma
Enrollment 195 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov